In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 American Heart Association Scientific Sessions. . . .
The New England Journal of Medicine: Search Results in Cardiology
Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease
In a study involving patients with Danon disease, AAV9.LAMP2B gene therapy appeared to be safe, increased cardiac LAMP2 expression, and was associated with clinical improvement over 24 to 54 months.
The New England Journal of Medicine: Search Results in Cardiology
Oral Infigratinib Therapy in Children with Achondroplasia
A phase 2 dose-finding study evaluated the safety and efficacy of infigratinib, an orally bioavailable FGFR1–3 selective tyrosine kinase inhibitor, in children with achondroplasia.
The New England Journal of Medicine: Search Results in Endocrinology
NEJM at AHA — Routine Spironolactone in Acute Myocardial Infarction
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Routine Spironolactone in Acute Myocardial Infarction
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Colchicine in Acute Myocardial Infarction
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
NEJM at AHA — Routine Spironolactone in Acute Myocardial Infarction
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 American Heart Association Scientific Sessions. . . .
The New England Journal of Medicine: Search Results in Cardiology
Colchicine in Acute Myocardial Infarction
In a randomized trial involving patients with acute myocardial infarction, colchicine did not decrease the risk of major adverse cardiovascular events over a median follow-up period of 3 years.
The New England Journal of Medicine: Search Results in Cardiology
Routine Spironolactone in Acute Myocardial Infarction
In a large trial involving patients with acute myocardial infarction, 95% of whom had ST-segment elevation myocardial infarction, spironolactone did not reduce the risk of cardiovascular events.
The New England Journal of Medicine: Search Results in Cardiology
NEJM at AHA — CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents